Table 3.
Characteristics of patients without or with grade 3–4 neurotoxicity (NTX).
| No NTX | Grade 3–4 NTX | |
|---|---|---|
| Number of patients | 48 | 13 |
| Age (mean ± SD) | 53 ± 14 | 57 ± 17 |
| % Female | 31% | 38% |
| Tisagenlecleucel/Axicabtasene Ciloleucel | 23/25 | 3/10 |
|
Pre-treatment CRP in mg/L (median; IQR) |
10; 38 | 33; 59 |
|
Occurrence of CRS (%) median CRS grade |
65% 1 |
100% 2 |
| Highest CRP within 4 days after reinjection in mg/L (median; IQR) | 34; 60 | 114; 155 |
| Lowest platelet count within 4 days after reinjection (median; IQR) | 102; 80 | 83; 102 |
| Highest ferritin within 4 days after reinjection (median; IQR); | 841; 1016 | 1996; 3334 |
| Treatment with Cefepim (%) | 13% | 31% |